491 related articles for article (PubMed ID: 7693435)
1. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Wilde MI; Langtry HD
Drugs; 1993 Sep; 46(3):515-578. PubMed ID: 7693435
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine (Retrovir) update.
Rachlis AR
CMAJ; 1990 Dec; 143(11):1177-85. PubMed ID: 2224694
[TBL] [Abstract][Full Text] [Related]
3. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
Kamali F
Clin Investig; 1993 May; 71(5):392-405. PubMed ID: 7685214
[TBL] [Abstract][Full Text] [Related]
5. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Graham NM; Hoover DR; Park LP; Stein DS; Phair JP; Mellors JW; Detels R; Saah AJ
Ann Intern Med; 1996 Jun; 124(12):1031-8. PubMed ID: 8633816
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD
Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987
[TBL] [Abstract][Full Text] [Related]
8. Zidovudine: five years later.
McLeod GX; Hammer SM
Ann Intern Med; 1992 Sep; 117(6):487-501. PubMed ID: 1503352
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD
Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705
[TBL] [Abstract][Full Text] [Related]
10. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
[TBL] [Abstract][Full Text] [Related]
12. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
Perry CM; Balfour JA
Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
[TBL] [Abstract][Full Text] [Related]
13. AIDS: Part II.
Kessler HA; Bick JA; Pottage JC; Benson CA
Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus infection in children.
Hoernle EH; Reid TE
Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
[TBL] [Abstract][Full Text] [Related]
15. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
Faulds D; Brogden RN
Drugs; 1992 Jul; 44(1):94-116. PubMed ID: 1379914
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
[TBL] [Abstract][Full Text] [Related]
18. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma.
Mitsuyasu RT
Br J Haematol; 1991 Oct; 79 Suppl 1():69-73. PubMed ID: 1931714
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
Bhana N; Ormrod D; Perry CM; Figgitt DP
Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma.
Fischl MA; Uttamchandani RB; Resnick L; Agarwal R; Fletcher MA; Patrone-Reese J; Dearmas L; Chidekel J; McCann M; Myers M
J Acquir Immune Defic Syndr (1988); 1991; 4(1):1-10. PubMed ID: 1670585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
